Stryker Stock EBITDA
| SYK Stock | EUR 371.50 2.20 0.60% |
Stryker fundamentals help investors to digest information that contributes to Stryker's financial success or failures. It also enables traders to predict the movement of Stryker Stock. The fundamental analysis module provides a way to measure Stryker's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stryker stock.
Stryker |
Stryker Company EBITDA Analysis
Stryker's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Stryker EBITDA | 4.04 B |
Most of Stryker's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stryker is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Stryker reported earnings before interest,tax, depreciation and amortization of 4.04 B. This is 360.43% higher than that of the Healthcare sector and significantly higher than that of the Medical Devices industry. The ebitda for all Germany stocks is 3.63% lower than that of the firm.
Stryker EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stryker's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Stryker could also be used in its relative valuation, which is a method of valuing Stryker by comparing valuation metrics of similar companies.Stryker is currently under evaluation in ebitda category among its peers.
Stryker Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 101.82 B | |||
| Shares Outstanding | 378.83 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 80.48 % | |||
| Price To Earning | 20.44 X | |||
| Price To Book | 5.77 X | |||
| Price To Sales | 4.90 X | |||
| Revenue | 18.45 B | |||
| Gross Profit | 11.65 B | |||
| EBITDA | 4.04 B | |||
| Net Income | 2.36 B | |||
| Cash And Equivalents | 1.84 B | |||
| Cash Per Share | 4.92 X | |||
| Total Debt | 11.86 B | |||
| Debt To Equity | 74.20 % | |||
| Current Ratio | 2.07 X | |||
| Book Value Per Share | 43.88 X | |||
| Cash Flow From Operations | 2.62 B | |||
| Earnings Per Share | 5.83 X | |||
| Price To Earnings To Growth | 2.82 X | |||
| Target Price | 287.72 | |||
| Number Of Employees | 51 K | |||
| Beta | 0.94 | |||
| Market Capitalization | 92.13 B | |||
| Total Asset | 36.88 B | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.10 % | |||
| Net Asset | 36.88 B | |||
| Last Dividend Paid | 2.84 |
About Stryker Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stryker's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stryker using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stryker based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Stryker Stock
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.